Clearside Biomedical, Inc.
NASDAQ: CLSD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- George Lasezkay
- Employees
- 32
- Headquarters
- Alpharetta, United States
- IPO year
- 2016
- Market cap
- $2.1M
- Website
- https://www.clearsidebio.com
Loading CLSD…
Loading profile data…Frequently asked questions about CLSD
What does Clearside Biomedical, Inc. (CLSD) do?
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pi...
Where does CLSD trade?
Clearside Biomedical, Inc. (CLSD) trades on the NASDAQ Global Market.
What sector is CLSD in?
Clearside Biomedical, Inc. (CLSD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clearside Biomedical, Inc.?
George Lasezkay is the chief executive officer of Clearside Biomedical, Inc. (CLSD).
Where is Clearside Biomedical, Inc. headquartered?
Clearside Biomedical, Inc. is headquartered in United States.
Does CLSD pay a dividend?
Clearside Biomedical, Inc. (CLSD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLSD go public?
Clearside Biomedical, Inc. (CLSD) completed its initial public offering in 2016.